Adamis Pharmaceuticals Liabilities 2024

Adamis Pharmaceuticals Aktienanalyse

What does Adamis Pharmaceuticals do?

Adamis Pharmaceuticals Corp is a biotechnology company based in the USA that specializes in the development of pharmaceuticals and medical devices. The company was founded in 2006 and is headquartered in San Diego, California. History: Adamis Pharmaceuticals was founded by Dr. Dennis J. Carlo, an experienced pharmaceutical executive with over 35 years of industry experience. The company initially focused on the development of therapeutics for the treatment of allergies and respiratory diseases. Over the years, the company has expanded its portfolio and specialized in the development of drugs for the treatment of anaphylaxis, asthma, and prostate cancer, as well as medical devices for drug delivery. Business model: Adamis Pharmaceuticals focuses on the development of novel drugs and medical devices that can improve patients' lives. The company seeks opportunities to meet unmet medical needs in existing therapy areas. Adamis collaborates closely with leading medical institutions and research facilities to develop and market a portfolio of innovative products. Various divisions: The company has various divisions, including: 1. Allergy/Respiratory: Adamis Pharmaceuticals has developed a broad portfolio of therapeutic agents for the treatment of allergies and respiratory diseases. The company has also developed a patented device called Symjepi, which is used to treat anaphylaxis, a life-threatening allergic reaction. This device also allows untrained individuals to self-treat in an anaphylaxis situation. 2. Oncology: Adamis Pharmaceuticals has developed a novel drug called TeloBlast®, which is used to treat prostate cancer. TeloBlast® targets telomerase, which is upregulated in many types of cancer. The company intends to develop additional drugs for the treatment of cancer in the future. 3. CNS: Adamis Pharmaceuticals has also developed innovative drugs for the treatment of CNS (central nervous system) disorders. The company plans to bring several new drugs for the treatment of neurological disorders to the market by 2022. 4. Medical devices: Adamis Pharmaceuticals has developed a range of patented medical devices, including the ZIM high-pressure injection pump, which allows doctors and nurses to administer medications quickly and accurately. Products: Adamis Pharmaceuticals' products include: 1. Symjepi: A patented device for the treatment of anaphylaxis. 2. TeloBlast®: A novel drug for the treatment of prostate cancer. 3. ZIM high-pressure injection pump: A patented medical device for drug administration. 4. Fluticasone/Salmeterol: An inhalable combination drug for the treatment of asthma and COPD (chronic obstructive pulmonary disease). Adamis Pharmaceuticals is an innovative biotechnology company specializing in the development of pharmaceuticals and medical devices. The company aims to meet unmet medical needs and improve patients' lives. With a broad portfolio of products and a strong commitment to research and development, Adamis Pharmaceuticals is well positioned to continue growing in the future. Adamis Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Adamis Pharmaceuticals's Liabilities

Adamis Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Adamis Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Adamis Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Adamis Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Adamis Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Adamis Pharmaceuticals stock

What is the level of liabilities of Adamis Pharmaceuticals this year?

Adamis Pharmaceuticals has a debt balance of 11.58 M USD this year.

What were the liabilities of Adamis Pharmaceuticals compared to the previous year?

The liabilities of Adamis Pharmaceuticals have increased by -6.71% dropped compared to the previous year.

What are the consequences of high debt for investors of Adamis Pharmaceuticals?

High liabilities can pose a risk for investors of Adamis Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Adamis Pharmaceuticals?

Low liabilities mean that Adamis Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Adamis Pharmaceuticals affect the company?

An increase in liabilities of Adamis Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Adamis Pharmaceuticals affect the company?

A decrease in the liabilities of Adamis Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Adamis Pharmaceuticals?

Some factors that can influence the liabilities of Adamis Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Adamis Pharmaceuticals so important for investors?

The liabilities of Adamis Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Adamis Pharmaceuticals take to modify the liabilities?

To change its liabilities, Adamis Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Adamis Pharmaceuticals pay?

Over the past 12 months, Adamis Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adamis Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Adamis Pharmaceuticals?

The current dividend yield of Adamis Pharmaceuticals is .

When does Adamis Pharmaceuticals pay dividends?

Adamis Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adamis Pharmaceuticals?

Adamis Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Adamis Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adamis Pharmaceuticals located?

Adamis Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adamis Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adamis Pharmaceuticals from 10/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/10/2024.

When did Adamis Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/10/2024.

What was the dividend of Adamis Pharmaceuticals in the year 2023?

In the year 2023, Adamis Pharmaceuticals distributed 0 USD as dividends.

In which currency does Adamis Pharmaceuticals pay out the dividend?

The dividends of Adamis Pharmaceuticals are distributed in USD.